Evidence map›Paper›PMID 27270293›Full record

Observational studyNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2016

Relationship of proximal tubular injury to chronic kidney disease as assessed by urinary kidney injury molecule-1 in five cohort studies.

Sushrut S Waikar, Venkata Sabbisetti, Johan Ärnlöv, Axel C Carlsson, Josef Coresh, Harold I Feldman, Meredith C Foster, Gudeta D Fufaa, Johanna Helmersson-Karlqvist, Chi-Yuan Hsu and 13 more

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 60 citations in OpenAlex.

  1. Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019
    Trial
  2. Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury: Findings From the ACCORD Trial Study Participants.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019
    Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Plasma proteomics of acute tubular injury.Nature communications · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Plasma Biomarkers as Risk Factors for Incident CKD.Kidney international reports · 2022
    Article
  15. Associations of Plasma Biomarkers of Inflammation, Fibrosis, and Kidney Tubular Injury With Progression of Diabetic Kidney Disease: A Cohort Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 9 institutions in 2 countries.

Sushrut S WaikarBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Venkata SabbisettiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Johan ÄrnlövUppsala University, Uppsala, Sweden Dalarna University, Falun, Sweden.
Axel C CarlssonUppsala University, Uppsala, Sweden Karolinska Institutet, Huddinge, Sweden.
Josef CoreshJohns Hopkins University, Baltimore, MD, USA.
Harold I FeldmanPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Meredith C FosterTufts Medical Center, Boston, MA, USA.
Gudeta D FufaaNational Institute of Diabetes and Digestive and Kidney Diseases.
Johanna Helmersson-KarlqvistUppsala University, Uppsala, Sweden.
Chi-Yuan HsuUniversity of California, San Francisco, San Francisco, CA, USA Kaiser Permanente Northern California, Oakland, CA, USA.
Paul L KimmelNational Institute of Diabetes and Digestive and Kidney Diseases.
Anders LarssonUppsala University, Uppsala, Sweden.
Yumin LiuBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Lars LindUppsala University, Uppsala, Sweden.
Kathleen D LiuUniversity of California, San Francisco, San Francisco, CA, USA.
Theodore E MifflinPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Robert G NelsonNational Institute of Diabetes and Digestive and Kidney Diseases.
Ulf RisérusUppsala University, Uppsala, Sweden.
Ramachandran S VasanBoston University, Boston, MA, USA.
Dawei XiePerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Xiaoming ZhangPerelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Joseph V BonventreBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Chronic Kidney Disease Biomarkers Consortium Investigators
Uppsala University · SEUniversity of Pennsylvania · USNational Institute of Diabetes and Digestive and Kidney Diseases · USBrigham and Women's Hospital · USHarvard University · USUniversity of California, San Francisco · USJohns Hopkins University · USKarolinska Institutet · SETufts Medical Center · US

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
Scientific and Data Coordinating Center(SDCC) for the P*U01DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FELDMAN, HAROLD I · 2001 to 2017
$50.1M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Zonulin Antibodies in Intestinal Permeabilitiy in IDDMM01RR016500 · NCRR · UNIVERSITY OF MARYLAND BALTIMORE · PI OSWALD, LYNN M · 2002 to 2009
$20.2M
Study of the Care and Outcomes of REnal InsufficiencyU01DK060902 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2001 to 2025
$19.5M
Limited Competition for the Continuation of the Chronic Renal Insufficiency CohorU01DK061021 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI RAHMAN, MAHBOOB · 2001 to 2025
$17.3M
Prospective Renal Insufficiency Cohort Evaluation:PRICEU01DK060984 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI COHEN, DEBBIE L · 2001 to 2025
$17.0M
Prospective Cohort Study of Chronic Renal InsufficiencyU01DK061028 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, PANDURANGA S · 2001 to 2025
$16.9M
Limited Competition for the Continuation of the Chronic Renal Insufficiency Cohort (CRIC) Hopkins Clinical CenterU01DK061022 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI APPEL, LAWRENCE JOHN · 2001 to 2025
$15.7M
NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1 TR000424NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR001878NCRR NIH HHS M01 RR016500NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR029879NHLBI NIH HHS HHSN268201100005CNHLBI NIH HHS HHSN268201100005GNHLBI NIH HHS HHSN268201100005INHLBI NIH HHS HHSN268201100006CNHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100007INHLBI NIH HHS HHSN268201100008CNHLBI NIH HHS HHSN268201100008INHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100009INHLBI NIH HHS HHSN268201100010CNHLBI NIH HHS HHSN268201100011CNHLBI NIH HHS HHSN268201100011INHLBI NIH HHS HHSN268201100012CNIDDK NIH HHS R01 DK072381NIDDK NIH HHS R01 DK093574NIDDK NIH HHS R01 DK139225NIDDK NIH HHS R37 DK039773NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01 DK060963NIDDK NIH HHS U01 DK060980NIDDK NIH HHS U01 DK060984NIDDK NIH HHS U01 DK060990NIDDK NIH HHS U01 DK061021NIDDK NIH HHS U01 DK061022NIDDK NIH HHS U01 DK061028NIDDK NIH HHS U01 DK085649NIDDK NIH HHS U01 DK085651NIDDK NIH HHS U01 DK085660NIDDK NIH HHS U01 DK085673NIDDK NIH HHS U01 DK085688NIDDK NIH HHS U01 DK085689NIDDK NIH HHS U01 DK104308NIGMS NIH HHS P30 GM103337
6 · The paper itself

Abstract

backgroundThe primary biomarkers used to define CKD are serum creatinine and albuminuria. These biomarkers have directed focus on the filtration and barrier functions of the kidney glomerulus even though albuminuria results from tubule dysfunction as well. Given that proximal tubules make up ∼90% of kidney cortical mass, we evaluated whether a sensitive and specific marker of proximal tubule injury, urinary kidney injury molecule-1 (KIM-1), is elevated in individuals with CKD or with risk factors for CKD.

methodsWe measured urinary KIM-1 in participants of five cohort studies from the USA and Sweden. Participants had a wide range of kidney function and were racially and ethnically diverse. Multivariable linear regression models were used to test the association of urinary KIM-1 with demographic, clinical and laboratory values.

resultsIn pooled, multivariable-adjusted analyses, log-transformed, creatinine-normalized urinary KIM-1 levels were higher in those with lower eGFR {β = -0.03 per 10 mL/min/1.73 m(2) [95% confidence interval (CI) -0.05 to -0.02]} and greater albuminuria [β = 0.16 per unit of log albumin:creatinine ratio (95% CI 0.15-0.17)]. Urinary KIM-1 levels were higher in current smokers, lower in blacks than nonblacks and lower in users versus nonusers of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

conclusionProximal tubule injury appears to be an integral and measurable element of multiple stages of CKD.

Indexed as

AdultAgedAlbuminuriaBiomarkersFemaleHepatitis A Virus Cellular Receptor 1HumansKidney Tubules, ProximalMaleMiddle AgedProspective StudiesRenal Insufficiency, ChronicRisk FactorsSwedenYoung AdultBiomarkersHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1albuminuriachronic kidney diseaseKIM-1

Identifiers

PMID27270293
PMCPMC5009290
OpenAlexW2417354843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.